- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT04828655
Analysis of Bioparametric Measures for Correlating Daily Habits and Reducing Blood Pressure
Análisis de Medidas bioparamétricas Para Correlacionar Los hábitos Diarios y Reducir la tensión Arterial
Studie Overzicht
Toestand
Conditie
Gedetailleerde beschrijving
In the Valencian Community, 93% of deaths appear to be related to (non-communicable) diseases such as: obesity, hypertension and diabetes. In 2013, cardiovascular diseases were the leading cause of death in women (34.4%) and the second in men (28.0%). There is a forecast that overweight and obesity will reach levels of 89% and 85% in men and women, respectively, by 2030. This will result in an increase in the obesity-related prevalence of coronary heart disease by 97%. The promotion of research on arterial hypertension and how it could be reduced is one of the basic pillars in decreasing the prevalence and incidence in the Spanish population. Research should anticipate and develop treatments and vaccines that prevent new scenarios of widespread infection.
Therefore, the main objective is to study the effects of the use of a mobile application plus recommendations based on a Mediterranean diet on the intake of micronutrients from natural sources (not drugs) on health indicators, cardiovascular parameters (blood pressure...), physical condition and body composition in the adult Spanish population.
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
-
Alicante, Spanje, 03690
- Alejandro Martínez Rodríguez
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Over 40 years old
- Healthy.
- Blood pressure levels slightly elevated but less than 140 mm Hg and/or diastolic pressure less than 90 mm Hg.
- Smartphone access
Exclusion Criteria:
- Subjects with diseases.
- Consumption of drugs and/or supplements.
- Subjects with food intolerances/allergies.
- Subjects with muscle or joint injury.
- Subjects with impossibility to follow up the intervention.
- Refusal of informed consent
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Preventie
- Toewijzing: Gerandomiseerd
- Interventioneel model: Crossover-opdracht
- Masker: Enkel
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Geen tussenkomst: CONTROL GROUP
Recommendations on healthy eating habits based on the Mediterranean diet and moderate physical activity.
Specific micronutrient intake focused on improving cardiovascular parameters and body composition.
|
|
|
Experimenteel: EXPERIMENTAL GROUP
Recommendations on healthy eating habits based on the Mediterranean diet and moderate physical activity through an application based on machine learning.
Intake of specific micronutrients focused on improving cardiovascular parameters and body composition.
|
Specific diet program and moderate physical activity, all guided and mediated by a mobile application.
As well as the recording and monitoring of periodic evaluations of health indicators.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Cardiovascular variables; heart rate.
Tijdsspanne: 9 months
|
Heart rate measurement done with an activity wristband.
|
9 months
|
|
Cardiovascular variables; blood pressure.
Tijdsspanne: 9 months
|
Measurement of blood pressure (systolic and diastolic) with a digital tensiometer.
|
9 months
|
|
Physical condition; time.
Tijdsspanne: 9 months
|
The evaluation of the physical condition will be carried out by means of the mile test, in which the subjects have to cover this distance walking, and in the shortest possible time.
|
9 months
|
|
Body Composition - Bioimpedance
Tijdsspanne: 9 months
|
Assessment of body composition using the TANITA (Tokyo, Japan) validated bioimpedance scale to obtain the results of fat mass, fat-free mass and visceral mass.
|
9 months
|
|
Weight
Tijdsspanne: 9 months
|
The weight of the subjects will be obtained using the TANITA (Tokyo, Japan).
From the body mass and height data, the BMI (kg/m2) will be obtained.
|
9 months
|
|
Height
Tijdsspanne: 9 months
|
The height of the subjects will be measured with the SECA 123 stadiometer (Hamburg, Germany).
From the body mass and height data, the BMI (kg/m2) will be obtained.
|
9 months
|
|
Body Composition - Skinfolds
Tijdsspanne: 9 months
|
The kinanthropometric assessment will be carried out using the methodology proposed for the restricted profile by the International Society for the Development of Kineanthropometry (ISAK).
The material used to measure skinfolds will be a plicometer.
|
9 months
|
|
Body Composition - Perimeters
Tijdsspanne: 9 months
|
The kinanthropometric assessment will be carried out using the methodology proposed for the restricted profile by the International Society for the Development of Kineanthropometry (ISAK).
The material used to measure perimeters will be a tape.
|
9 months
|
|
Body Composition - Diameters
Tijdsspanne: 9 months
|
The kinanthropometric assessment will be carried out using the methodology proposed for the restricted profile by the International Society for the Development of Kineanthropometry (ISAK).
The material used to measure diameters will be a pachymeter.
|
9 months
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Alejandro Martínez Rodríguez, Alicante University
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- UA-2020-04-16
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Hart-en vaatziekten
-
University of PennsylvaniaVoltooidPatiënten met primaire of secundaire diagnose Code of Intrntl Classification of Diseases, 9th Revision, (ICD-9-CM) 410 (Behalve wanneer het 5e cijfer 2 was)Verenigde Staten
-
SpringWorks Therapeutics, Inc., a healthcare company...VerkrijgbaarNeurofibromatose Type 1-geassocieerde plexiforme neurofibromen | Histiocytisch neoplasma | Andere MAP-K Pathway Driven Diseases